| AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$95 |
Appendix 4G
|
13 Feb 2026 9:52AM |
$1.090 |
$1.080 |
fallen by
0.92%
|
|
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,559 |
Appendix 3C
|
13 Feb 2026 9:52AM |
$37.320 |
$36.360 |
fallen by
2.57%
|
|
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$304 |
AKD2500 Next-Generation Silicon Project
|
13 Feb 2026 9:51AM |
$0.145 |
$0.135 |
fallen by
6.90%
|
|
BRN - Price-sensitive ASX Announcement
Full Release
Key Points
- BrainChip Holdings Ltd initiates the AKD2500 silicon project as a strategic advancement of the Akidaâ„¢ 2.0 platform roadmap.
- The AKD2500 will be fabricated using TSMC's 12nm process technology.
- The total project budget is approximately US$2.5 million, covering development services, fabrication, packaging, testing, and third-party technology licensing.
- The project represents a significant investment in BrainChip's growth strategy and aims to leverage Edge AI's low-power processing capabilities.
- Development activities are scheduled across staged milestones, with prototype silicon expected by Q3 2026.
- The project involves partnerships with ASICLAND Co. Ltd for design support and fabrication coordination.
- BrainChip retains ownership of its proprietary Akidaâ„¢ technology platform IP, with the project including third-party IP licensing.
- The AKD2500 is a technology development initiative without customer orders or commercial supply commitments included.
- The project aims to strengthen BrainChip's position in high-growth verticals such as defense, industrial, consumer, and intelligent sensing.
- CEO Sean Hehir emphasizes the strategic use of capital for advancing technology roadmap and future customer engagement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NewPeak Metals Limited (NPM) ORDINARY FULLY PAID |
Materials |
$9 |
Drilling Completed at Tansey Gold Project
|
13 Feb 2026 9:49AM |
$0.023 |
$0.026 |
risen by
13.04%
|
|
| Felix Gold Limited (FXG) ORDINARY FULLY PAID |
Materials |
$162 |
NW Array Drilling Confirms Extension to Gold Mineralisation
|
13 Feb 2026 9:48AM |
$0.380 |
$0.330 |
fallen by
13.16%
|
|
FXG - Price-sensitive ASX Announcement
Full Release
Key Points
- Felix Gold (ASX:FXG) reported results from drilling and trenching at NW Array, confirming extensions to gold mineralisation.
- High-grade gold results include 47.36m at 1.34 g/t Au and 15.71m at 2.91 g/t Au.
- The NW Array prospect hosts both antimony and gold mineralisation.
- Gold mineralisation forms halos around antimony-bearing structures.
- The mineralised system remains open along strike and at depth.
- The prospect is located 30km from Kinross Gold’s Fort Knox mill, offering potential processing pathways.
- Felix Gold is advancing a U.S.-based antimony supply chain alongside its gold portfolio.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tribeca Global Natural Resources Limited (TGF) ORDINARY FULLY PAID |
Financials |
$195 |
January 2026 - NTA Statement
|
13 Feb 2026 9:48AM |
$2.840 |
$2.640 |
fallen by
7.04%
|
|
| Tasman Resources Limited (TAS) ORDINARY FULLY PAID |
Materials |
$30 |
Change in substantial holding - 7 Enterprises Pty Ltd
|
13 Feb 2026 9:47AM |
$0.061 |
$0.067 |
risen by
9.84%
|
|
| WAM Strategic Value Limited (WAR) ORDINARY FULLY PAID |
Financials |
$211 |
Geoff Wilson Appendix 3Y
|
13 Feb 2026 9:46AM |
$1.165 |
$1.170 |
risen by
0.43%
|
|
| Ronin Resources Ltd (RON) ORDINARY FULLY PAID |
Materials |
$11 |
Pause in Trading
|
13 Feb 2026 9:45AM |
$0.270 |
$0.270 |
fallen by
0%
|
|
RON - Price-sensitive ASX Announcement
Full Release
Key Points
- Pause in trading of Ronin Resources Ltd securities.
- Trading halt pending further announcement.
- Compliance with ASX Listings requirements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bio-Gene Technology Ltd (BGT) ORDINARY FULLY PAID |
Materials |
$9 |
Flavocide Acute Neurotoxicity Study Underway
|
13 Feb 2026 9:45AM |
$0.031 |
$0.031 |
fallen by
0%
|
|
| WAM Alternative Assets Limited (WMA) ORDINARY FULLY PAID |
Financials |
$201 |
January 2026 Investment Update
|
13 Feb 2026 9:44AM |
$1.030 |
$1.020 |
fallen by
0.97%
|
|
| AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$95 |
Form 8-K
|
13 Feb 2026 9:43AM |
$1.090 |
$1.080 |
fallen by
0.92%
|
|
AVH - Price-sensitive ASX Announcement
Full Release
Key Points
- AVITA Medical reported a net loss of $11.6 million for the fourth quarter of 2025.
- Total revenue for the quarter was $17.6 million, a decrease of 4% compared to the same period in 2024.
- The company secured a new credit facility with Perceptive Advisors LLC for up to $60 million.
- AVITA Medical's full-year 2025 revenue increased by 11% to $71.6 million.
- The gross profit margin for the year was 82.1%.
- AVITA Medical focused on reducing operating expenses and improving cash efficiency.
- The RECELL product continues to gain Medicare reimbursement coverage.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$428 |
Strong Returns Boost Dividend to 8c, Dividend Policy Update
|
13 Feb 2026 9:43AM |
$2.930 |
$2.940 |
risen by
0.34%
|
|
| AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$95 |
AVITA Q4 and FY25 Earnings Presentation
|
13 Feb 2026 9:42AM |
$1.090 |
$1.080 |
fallen by
0.92%
|
|
AVH - Price-sensitive ASX Announcement
Full Release
Key Points
- Delivered stable revenue performance in Q4 2025.
- Improved reimbursement clarity and utilization normalization at burn and trauma centers.
- Advanced post-market clinical programs for Cohealyx and PermeaDerm.
- Financial results: FY 2025 revenue $71.6M, operating expenses $101.4M, net loss $48.6M.
- Secured new debt facility with Perceptive Advisors LLC to refinance existing debt.
- 2026 growth expectations with revenue guidance of $80 to $85 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alicanto Minerals Limited (AQI) ORDINARY FULLY PAID |
Materials |
$215 |
Cleansing Notice
|
13 Feb 2026 9:42AM |
$2.300 |
$2.020 |
fallen by
12.17%
|
|
| AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$95 |
AVITA Reports Q4 and Full Year 2025 Financial Results
|
13 Feb 2026 9:41AM |
$1.090 |
$1.080 |
fallen by
0.92%
|
|
AVH - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for Q4 2025 was $17.6 million, a decrease from Q4 2024.
- Full year 2025 revenue was $71.6 million, an 11% increase from 2024.
- Gross profit margin for Q4 was 81.2%, and for the full year was 82.1%.
- Net loss for 2025 was $48.6 million, improved from $61.8 million in 2024.
- The company refinanced its debt under a new facility with Perceptive Advisors.
- Financial guidance for 2026 predicts a 12% to 19% revenue growth.
- AVITA's product RECELL received broader Medicare reimbursement coverage.
- The company focused on improving cash efficiency and reducing costs in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$112 |
Notice Under Section 708A
|
13 Feb 2026 9:41AM |
$0.093 |
$0.093 |
fallen by
0%
|
|
| Alice Queen Limited (AQX) ORDINARY FULLY PAID |
Materials |
$19 |
Application for quotation of securities - AQX
|
13 Feb 2026 9:41AM |
$0.011 |
$0.011 |
fallen by
0%
|
|
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$428 |
Dividend/Distribution - RG8
|
13 Feb 2026 9:41AM |
$2.930 |
$2.940 |
risen by
0.34%
|
|
| AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$95 |
Appendix 4E and Annual Report (Form 10-K)
|
13 Feb 2026 9:40AM |
$1.090 |
$1.080 |
fallen by
0.92%
|
|
AVH - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss decreased to $48.6 million from $61.8 million.
- Total revenues grew to $71.6 million.
- Cash and cash equivalents amounted to $10.2 million.
- Operating expenses increased, affecting profitability.
- Strategic initiatives focused on market expansion and product development.
- Executed agreements and amendments to bolster operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$112 |
Application for quotation of securities - ALA
|
13 Feb 2026 9:40AM |
$0.093 |
$0.093 |
fallen by
0%
|
|
| Evergold Minerals Limited (EG1) ORDINARY FULLY PAID |
Materials |
$9 |
Cleansing notice under section 708A(5)(E) of Corps Act
|
13 Feb 2026 9:39AM |
$0.040 |
$0.035 |
fallen by
12.50%
|
|
| Austral Resources Australia Ltd (AR1) ORDINARY FULLY PAID |
Materials |
$170 |
Drilling to Commence at Rocklands
|
13 Feb 2026 9:39AM |
$0.105 |
$0.100 |
fallen by
4.76%
|
|
AR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Austral Resources Australia Ltd (ASX:AR1) announced the commencement of a drilling campaign at Rocklands targeting improved confidence in the Cu-Au mineral resource.
- The drilling will include an 18-hole RC/DDH programme covering 2,567 meters aimed at the Las Minerale and Double Oxide Cu-Au prospects.
- The programme aims to validate the geological and mineralisation controls and improve confidence in the existing Rocklands mineral resource estimate.
- The initiative will also include targeted metallurgical and comminution test work to assess processing assumptions such as flotation response and grinding behavior.
- Austral plans to deliver results progressively through Q3 2026 to support further resource definition and processing optimisation studies.
- The Rocklands Processing Plant is a large-scale Cu-Au sulphide flotation facility with a 3.0 Mtpa capacity, affected historically by throughput imbalances.
- Austral is focused on plant optimisation, addressing debottlenecking opportunities across the circuit, including SAG mill integration.
- The company aims to produce 50,000 tonnes of copper per year from the Mt Isa–Cloncurry region and position itself as a regional processing hub.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alice Queen Limited (AQX) ORDINARY FULLY PAID |
Materials |
$19 |
Application for quotation of securities - AQX
|
13 Feb 2026 9:39AM |
$0.011 |
$0.011 |
fallen by
0%
|
|
| St George Mining Limited (SGQ) ORDINARY FULLY PAID |
Materials |
$377 |
Government Financial Support for Araxa
|
13 Feb 2026 9:39AM |
$0.096 |
$0.099 |
risen by
3.13%
|
|
SGQ - Price-sensitive ASX Announcement
Full Release
Key Points
- St George Mining Limited received government tax exemptions for Araxá Project.
- The project is located in Minas Gerais, Brazil, with significant niobium and rare earths resources.
- Preferential goods tax regime to reduce development costs by up to 18%.
- A joint venture with CEFET to establish a technological centre at Araxá.
- Government support includes a Memorandum of Understanding for developing domestic supply chains.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.